Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Background: Globally, of the 248 million people chronically infected with the hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs) have been approved for the treatment of chronic hepatitis B (CHB) in China. Objectives: The aims of this study were to determine r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Kerui, Liu, Li-Ming, Farazi, Paraskevi A., Wang, Hongmei, Rochling, Fedja A, Watanabe-Galloway, Shinobu, Zhang, Jian-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827725/
https://www.ncbi.nlm.nih.gov/pubmed/29447614
http://dx.doi.org/10.1080/16549716.2018.1433987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827725/
https://www.ncbi.nlm.nih.gov/pubmed/29447614
http://dx.doi.org/10.1080/16549716.2018.1433987

Ejemplares similares